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Abstract
Biopharmaceutical companies are under constant pressure to deliver double-digit growth. In
traditional markets such as the U.S., Japan, and the European Union growth is stagnant, and
profit margins are falling due to increased price pressure from governments. As a result
companies are looking to expand their customer bases. They see such opportunities in the
emerging markets of China, India, and Eastern Europe where growth rates are in the double-
digits. However, there are risks and uncertainties associated with expansion into emerging
markets. These countries lack the regulatory systems and contract-enforcing mechanisms that
most companies are used to operating under. In addition, pricing pressure from patients,
governments, and healthcare organizations increases attention to the cost of goods.
This document develops a framework for analyzing the potential for introducing a
pharmaceutical product into a predetermined emerging market. The framework includes three
steps. The first step is market assessment. The second step focuses on the supply chain.
Information from market research is used to propose and evaluate alternative operational
structures, to reduce costs, and to facilitate market entry. The third step involves financial
modeling using Monte Carlo Simulation to account for uncertainty in the information collected
from the market assessment and supply chain analysis. The framework is applied in a case study
which involves the Genzyme Corporation and evaluates the Chinese market for its cholesterol
lowering drug, Cholestagel.
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1 Introduction
1.1 Genzyme Corporation
Genzyme is a biopharmaceutical company with healthcare products for serious diseases. This
year marks the 25 anniversary of Genzyme's founding. Since 1981, it has grown from a small
start-up into a global leader within the industry, with more than 7,600 employees in 30 countries
and product sales in 80 countries. The company's products and services are focused on rare
inherited disorders, kidney diseases, orthopedics, cancer, transplantation and immune disease,
and diagnostic testing. Figure 1-1 shows major product contribution to Genzyme Corporate
2005 revenue of $2.7 billion (1).
Genzyme Revenue by Product
Annual Revenue = $2.7 Billion
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Figure 1-1: Genzyme Product Portfolio-Contribution to Annual Revenue in 2005
Genzyme is arguably best known for its recombinant protein therapeutic product line (Cerezyme,
Aldurazyme, and Fabrazyme) for the treatment of lysosomal storage disorders. These three
products accounted for nearly 50% of 2005 corporate revenues, which is noteworthy considering
that these drugs treat a combined global patient population of approximately 6,500. Genzyme is
successful in serving such small patient populations in part because it is actively involved in
teaching doctors around the world how to identify these particular disorders. In addition, they
commonly work with insurance groups and/or government agencies to get medical treatment for
patients. Genzyme's experience in small patient populations along with its vision of meeting
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unmet medical needs of communities worldwide has given Genzyme a global outlook for all of
its products. As part of the Genzyme vision, the company will exhaustively comb the entire
globe to find opportunities for their existing products.
Genzyme actively pursues opportunities to bring in new technology in medical areas where they
have a presence and expertise, and in emerging areas where they would like to build a business.
Though Genzyme is widely known for its biologics, it is hoping to expand its presence in the
small molecule and polymer drug markets as well.
In 2000, Genzyme acquired GelTex Pharmaceuticals for its polymer technology platform and
obtained two patent-protected and marketed products, Renagel and WelChol. Renagel is a
polymer product used to treat end-stage renal disease for patients undergoing dialysis. In 2005,
it was Genzyme's second largest revenue generator at $418 million. WelChol is a polymer based
cholesterol lowering agent currently marketed by Sankyo-Parke Davis. This partnership was
inherited with the acquisition of GelTex and is limited to the U.S. market. Genzyme controls the
rights to market the cholesterol lowering drug under the brand name Cholestagel outside of the
U.S. These products bring Genzyme into the market of drug conditions that affect large
populations, and are considered important to the company's future growth.
1.2 Project Motivation and Setting
Since 2000, Genzyme has been experiencing impressive growth rates of on average 29% per
year (2). This success has occurred in part because of Genzyme's commitment to increase
diversification of their product portfolio as well as to broaden their worldwide reach. To create
long-term sustainability, Genzyme continues to seek opportunities to expand their customer base
for their existing products, and see one such opportunity to increase global sales in the emerging
markets of China.
China recorded the highest growth rate in the pharmaceutical sector of any single country, up
28% from $7.4bn in 2003 to $9.5 billion in 2004 (3). It is currently the ninth largest
pharmaceutical market, but is projected to overtake Germany's position as the fourth largest by
2015. Even so, there are a lot of risks and uncertainties associated with expansion into this
market. China has complex regulations and distribution networks, as well as lax enforcement of
intellectual property laws. In addition, the purchasing power of patients, governments, and
healthcare organizations is low. Such a market is unlikely to yield short-term gains.
Genzyme has no illusions about the time and difficulty involved with building presence in an
emerging market such as China. In early 2005, Genzyme started an internal effort, the China
Initiative Group, to better understand the pharmaceutical market environment in China and
coordinate efforts to bring Genzyme products into China. Two offices were opened in 2005, one
in Beijing and another in Shanghai. Numerous trips to China were taken through the latter half
of the year to assess manufacturing capabilities and to begin talks with regulatory officials.
Genzyme is considering taking Cholestagel, their cholesterol lowering drug, into the urban
Chinese market and created a six-month internship to evaluate this opportunity in the fall of
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2005. The framework developed and the analysis that follows come from information gathered
through a variety of sources including literature reviews, organization-wide interviews and
internal resources, and data gathered from primary market research in China.
1.3 Framework
This document develops a framework for analyzing the potential for introducing a
pharmaceutical product into a predetermined emerging market, and details how the framework
was applied during an internship at the Genzyme Corporation. The framework includes three
steps, as illustrated in Figure 1-2. The first step is market assessment. The second step focuses
on the supply chain. Information gleaned from market research is used to propose and evaluate
alternative operational structures, to reduce costs, and to facilitate market entry (satisfying
regulatory and/or product costs requirements). The third step involves financial modeling. The
focus is on analytic tools that explicitly account for uncertainty in the information collected from
market assessment and supply chain analysis. The focus of this work is on economic evaluation
and risk assessment. We recognize that non-economic, strategic factors can also influence a
company's decision to enter a new market, but these factors are not studied in this thesis.
Framework for analyzing biopharmaceutical product introduction
in an emerging market
Step 3) Financial Modeling
- NPV
* Monte Carlo
Simulation
Yes or No
Figure 1-2: Graphical Representation of the Framework utilized for analyzing
biopharmaceutical product introduction in an emerging market
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1.4 Thesis Overview
The remainder of the thesis is organized as follows:
o Chapter 2: Overall Market Potential
In Chapter 2 we define the six focus areas of market assessment. The information
gathered specific to Cholestagel gives a much clearer look at the cholesterol lowering
market in China and Cholestagel's product positioning in this competitive environment.
o Chapter 3: Supply Chain Evaluations
Chapter 3 describes the major factors used to assess supply chain alternatives. This
includes a look at the firm's internal capabilities, and a comparison with alternatives
available in the market place. The chapter maps out the current Cholestagel supply chain
and discusses the alternatives considered and eliminated for the China Market.
o Chapter 4: Financial Evaluation Techniques
In Chapter 4, we describe two financial analysis tools typically used in project evaluation
and their relative strengths and weaknesses. The main focus will be on Monte Carlo
Simulation, a sophisticated technique that allows the user to visually capture the range of
outcomes associated with a project. This chapter will show the equation used to calculate
expected returns from the Cholestagel venture, speak to the critical assumptions made
during equation formulation, and display Monte Carlo simulation results. We wrap up
with a final recommendation for the case study examined
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2 Market Potential
This framework emphasizes a data-driven approach to evaluating emerging markets. In
Appendix A we look at some of the challenges associated with collecting international marketing
data, and suggest ways in which to obtain free or low-cost information.
Market research methods fall into two basic categories: primary and secondary. In primary
research original data is collected through focus groups, surveys, or one-on-one interviews from
current and prospective customers. In secondary research, data is collected from existing sources
such as reference books, industry publications, and government agencies.
In assessing the market potential, we adopted an existing product strategy framework developed
by Putnam Associates (4). Putnam's product strategy framework defines six broad categories:
patients, physicians, payors, product, competitive landscape, and regulatory climate. In the
context of this thesis, these categories were used to structure the market research and information
gathering activities as detailed below. The information gathered through these activities will
then feed into the decision making with regards to operations strategy (chapter 3) and provides
valuable data to develop more reliable forecast models (chapter 4).
2.1 Patients
Analyzing market potential for a pharmaceutical drug begins with identifying and understanding
the patients and their needs. Four key determinants in this category include prevalence,
incidence, awareness, and influence. Prevalence gauges the number afflicted with a disease and
gives a sense of the market opportunity. The growth rate or incidence of a disease predicts the
future market size. In some developing countries, healthcare infrastructure is poor and affects the
number of patients who are familiar with or treated for a disease. Awareness rate and treatment
rate affect the market opportunity represented by prevalence and determines the importance or
need for marketing activity. Finally, who or what influences a patient can help focus the
manager's marketing efforts.
2.2 Physicians
When it comes to medical needs, patients will often rely on medical expertise to guide them in
their purchasing behavior. Therefore, though patients are the business end consumer, physicians
are typically the main customer. It is important to identify what types of physicians (e.g.,
generalists vs. specialists) patients turn to for a particular disease category. Knowing why
doctors prescribe a specific drug, or what characteristics might drive their prescription behavior,
may help with developing product messaging. Equally important is learning what mediums
physicians often rely upon for learning about new medical products.
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2.3 Payors
A major stakeholder in the healthcare system involves the payor. Payors can take various forms
including patients that self-pay, patients covered by government insurance schemes, or private
insurance systems. If they involve insurance schemes business managers should also understand
the characteristics of the different plans offered to most patients. The offered plans may limit the
selection of drugs covered based on the value proposition or price. Healthcare can be especially
expensive for those battling chronic illnesses. Because each of the insurance schemes affects
how much patients end up paying for their healthcare, they may also have a major influence on
product choice.
2.4 Product Attributes
Product placement in the new market requires an in-depth understanding of the product
technology and relevant history. Business managers must know the product's disadvantages and
competitive advantages. This information should allow the firm to understand how the product
might meet customer needs or how it can distinguish itself from the competition. Often this
combined information can help shape company marketing messages and activities.
2.5 Competitive Situation
The company standing in the market place and the strategic direction undertaken will largely
depend on the existing competitive situation as well as future entrants or treatments. A firm
must identify local and foreign competitors. If there are competitors, competitor analysis allows
a firm to benchmark successful and unsuccessful market entry strategies undertaken by pioneers.
The firm may also be able to identify unmet medical needs by assessing the strengths and
weaknesses of the competition. The competitor pricing structure will also give insights into
supply demand market equilibrium and help a firm choose a pricing strategy.
2.6 Government Policies
The pharmaceutical industry from manufacturing to marketing is entirely affected by
government regulations. As a result, success and growth in this industry is heavily influenced by
government policies. Import tax laws, pricing policies, or the existence of state-subsidized firms
may make it difficult for an entering firm to compete. In developing countries, sometimes it is
the lack of policy or limited experience with a new policy, such as intellectual property
protection, which makes the market risky for the firm.
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Figure 2-1: Market Assessment Focus Areas (4)
Focus Determinants of Description
Area.- VlIP I I
2.7 China Market Assessment: Cholestagel
The information in the analysis below comes from a variety of sources, including literature
reviews, organization-wide interviews and internal resources, and data gathered from primary
market research in China detailed in Appendix B.
Hypercholesterolemia/hyperlipidaemia, is a form of lipid metabolism disorder, where overall
cholesterol levels in the bloodstream are excessively high. The lipid families of concern include
low density lipoproteins and high density lipoproteins. The lipid families are described below.
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o Low density lipoproteins (LDL) are a major cholesterol carrier in the blood and are often
known as 'bad' cholesterol. High levels of LDL can cause plaque build-up in the arteries
leading to a narrowing of blood vessels. Blocked arteries that feed the brain can result in
a stroke and blocked arteries that feed the heart can result in a heart attack.
o High density lipoproteins (HDL) carry cholesterol away from the arteries back to the
liver where it is excreted from the body. They are often known as 'good' cholesterol
because they are believed to slow plaque growth in blood vessels.
The guidelines set out by the U.S. National Cholesterol Education
diagnosing the disorder is seen in Figure 2-2.
Program (NCEP) for
Total Cholesterol
< 200 mg/dL
200-239 mg/dL
> 240 mg/dL
LDL Cholesterol Level
< 100 mg/dL
100-129 mg/dL
130-159 mg/dL
160-189 mg/dL
> 190 mg/dL
HDL Cholesterol
< 40mg/dL
> 60 mg/dL
Category
Desirable
Borderline High
High
Category
Optimal
Near optimal/above optimal
Borderline High
High
Very High
Category
Risky
Desirable
*Cholesterol levels are measured in milligrams of cholesterol per deciliter of blood
Figure 2-2: NCEP Guidelines for Cholesterol Diagnosis (5)
Prevalence & Incidence
Hypercholesterolemia is a disorder that typically affects developed countries. Table 2-1 shows
the prevalence rate in seven major pharmaceutical markets and compares that with prevalence in
China. Hyperlipidaemia affects over 100 million people in China, which is over twice that in
Germany and about 80% of that in the US. As China becomes more industrialized, we expect
this number to rise rapidly, especially in the urban population.
Table 2-1: Prevalence of Hypercholesterolemia (6)
China* US Japan France Germany Italy Spain UK
Prevalence (million) 117.3 142.2 25.7 30.9 53.8 19.8 9.0 31.3
Rate (%) 9 49 20 52 65 35 23 53
In Figure 2-3 we see that 68% of hyperlipidaemia cases in China are in the borderline risk
category for the disorder. This group requires 23% to 38% lipid lowering to reach the optimal
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LDL level of <100mg/ml as defined by the NCEP. Only 11% are in the very high risk category
and these patients would require over 50% lipid lowering to reach optimal LDL levels.
Total: 117 million cases
very high
(> 190mg/dL)
high 11%
(160-189 m(
21%
borderline
130-159 md/dL)
68%
Figure 2-3: Breakdown of Hyperlipidaemia Cases in China (7)
Influence
In the past, the government's control over advertising of medical products in China was lax, with
Chinese manufacturers often making extravagant claims for products. Since 2001, under new
regulations, advertising of prescription drugs in the mass media has been banned and is only
permitted in approved medical and trade journals (8). Without the direct to consumer marketing
of pharmaceuticals products in China, patients will more likely rely on their physicians for
medical advice.
Prescription Driver
The vast majority of all medical benefits are provided through hospitals and other health care
facilities. The public hospital sector is segmented into 3 tiers:
* Tier III: Academic/Medical; highest level
* Tier II: Smaller Cities
* Tier I: Rural Communities; lowest level
In the 16 major urban cities, patients typically go to Tier III (top level hospital) for treatment,
and then perhaps to a Tier II for follow-up, but continue with the prescription handed out from a
Tier III level physician (9). Therefore to be cost efficient, branded pharmaceutical products
should focus marketing/sales efforts to the Tier III and Tier II hospitals.
Over the years, because of low government funding, hospitals support themselves through the
sale of prescription products. As a results, pharmaceutical sales at hospitals account for a little
less than 80% of the pharmaceutical market, Figure 2-4. It is important to gain support from
doctors in the hospitals because they affect what drugs are carried in the hospitals. Based on our
market research, we also found that doctors take into considering drug reimbursement when they
prescribe drugs.
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OTC drugs
22.5%
sourced
drugs
77.5%
Figure 2-4: Pharmaceutical Market Sector in 2004 (10)
Education & Promotion
Promotional efforts should be focused on the 3 main channels doctors listed during our market
research as their sources for new product information (Figure 2-5)
o Medical Journals (89% of doctors interviewed use this type of education channel)
o Symposium (85%)
o Company Representative Introduction (63%)
Information Channel
- Medicaljournak
Medical symposiun
"feps' introductio
Internal hospital l
department sympos iums
Other doctors
Introductions
The direct mails from
phammaceutical compan
Website
NW 89%
85%
:4% 3%
0% 20% 40% 0% 80% 10
0% 20% 40% 60% 80% 100
% of d octor
N=160
Figure 2-5: Information Channels Typically Utilized by Physicians
In China, there is a significant income disparity between the urban and rural areas. Though
China's population stands at approximately 1.3 billion, the affluent population represents only
about 10% of that and is concentrated along the eastern region of the country in 16 cities:
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Beijing, Chengdu, Chongqing, Dalian, Guangzhou, Haerbing, Hangzhou, Tianjin, Shenyang,
Shanghai, Qingdao, Nanjing, Ji'nan, Wuhan, Xi'an, and Zhengzhou.
In addition to the income disparity, there is a huge disparity in access to healthcare and
insurance. The Chinese Government switched from a free health care system to a partial
provider-pay system in the late 1990s as part of their political-economic transition to a free
market economy. As a result, China's large rural population could no longer afford healthcare,
and many were forced to pay for the major share of their medical services out of their own
pockets. Therefore, purchasers in China are extremely price sensitive. In the urban areas,
insurance schemes do exist. The Ministry of Labor and Social Security delegated responsibility
for implementing an insurance scheme to regional administrations, and therefore schemes differ
from region to region.
Reimbursement (7)
A patient can only be reimbursed for drugs listed on the insurance system reimbursement list.
The national reimbursement list is controlled by the central government. However, each of
China's provinces (regional governments) will have its own list to suit the particular needs of its
province. For most provinces, a drug will only qualify onto the reimbursement list after it has
been on the Chinese market for 2 years and has proved to be cost-effective. Each province may
require additional price reduction from the market entry price in order for the drug
manufacturer's drug to be approved for the list.
Genizyme's Cholesterol Lowering Agent: Cholestagel
Cholestagel, colesevelam hydrochloride, is a specifically engineered polymer based bile acid
sequestrant used to treat hypercholesterolemia. It is currently approved in the U.S., and was
successfully marketed there by Sankyo U.S. under the brand name WelChol since 2000.
WelChol is the highest selling bile acid sequestrant on the U.S. market with sales of
approximately $170 million per year for the treatment of hyperlipidaemia.
Below we discuss some of the key advantages and disadvantages that were noted during our
primary research in China, see Appendix B for more details.
Advantages
o Effective as Combination Therapy (41% of 160 physicians interviewed)
Co-administration of Cholestagel and a low dose statin has been shown to provide LDL
cholesterol lowering beyond using either therapy alone. 41% of the physicians saw
combination therapy as a product advantage. Honghui Medicines acknowledged that
more and more doctors are becoming interested in combination therapy drugs (11).
o Non-systemic mode of action (34%)
Hepatitis B, a disease of the liver, is a large problem in the Chinese market with over 100
million people chronically affected (12). Cholestagel lowers LDL-C levels without
entering the circulatory system. In contrast to statins, at no time does the product enter or
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act on the liver or kidneys and no liver function monitoring is required of patients on
Cholestagel. 34% of physicians noted this as a key advantage of the product.
o Side effects (26%)
In 2001, Bayer's statin product Lipobay was pulled from the market after a number of
deaths occurred when the drug was combined with gemifibrozil. The bad publicity
surrounding the deaths increased doctors' concerns about the side effects of high does of
statins.
Disadvantages
o Big Tablet/Poor Patient Compliance (21%)
Physicians typically prescribe 10mg statins to their patients. The Cholestagel treatment
regiments require patients to take six 625mg tablets every day, or over 300 times the
daily load of a statin. This large tablet load may not be well tolerated by older patients
and is an additional burden to patients who have other medicinal requirements.
o Monotherapy not as effective as competitor product (21%)
As a monotherapy, Cholestagel has been shown to lower LDL cholesterol on average 15-
18%. Though this LDL lowering will be sufficient for those with borderline cholesterol
risk, it is not as effective as a 10mg dose of statin which in the case of atorvastatin
(generic form of Pfizer's Lipitor) has been shown to lower LDL cholesterol on average
39% (13).
o High Price (16%)
A daily dose of Cholestagel is more expensive to produce than a daily dose of statin, in
part because of the sheer quantity of the drug that needs to be consumed. In the U.S. it
has commanded a price premium above most statins because many patients who cannot
tolerate statins will turn to it as an alternative treatment. In China, those who cannot
tolerate statins will turn to Traditional Chinese Medicines, TCMs, which cost less than 15
cents for a daily dose. Unless the drug can be reimbursed through insurance, the high
price of the treatment will mean that only those with a high income level can afford the
drug.
Anti-hyperlipidaemia mparket
Market Size (14)
In the U.S., the hyperlipidaemia market in 2005 was approximately $15.5 billion. Based on the
sheer number of hyperlipidaemia cases seen in China (similar numbers to the U.S.), we would
have expected a very sizable anti-hyperlipidaemia market. However, IMS (company that
specializes in the collection of health information) data analysis shows that the entire China
hyperlipidaemia market in 2005 was $92 million ($54 million for 16 major urban markets), with
a little over 0.77 million patient cases. The market had impressive growth of 28% in 2004 and
again in 2005, Table 2-2.
MIT Thesis - Hong T. Hong Page 17 of 45
US China
Statistical Prevalence (2004) 142 m 117 m
Hypercholesterolemia market (2005) $15.5 bn $92 m
CAGR% est 5% 28%
Cholestagel/Welchol Revenue (2005) S170 m (1.1%) n/a
Table 2-2: Anti-hyperlipidaemia market in the US and in China
Based on IMS data, combined with conversations with persons experienced with the sales of
hyperlipidaemia drugs in China, we expect continued rapid growth in this market. In Figure 2-6,
we see the projected market size for 16 major urban markets through 2014 (patent life of
Cholestagel) assuming 30%, 40% and 50% growth. Even with 50% growth for the next 8 years,
the market stands at only $2.1 billion or less than 20% of the 2005 U.S. hyperlipidaemia market.
$2,500
$2,000
$1,500
$1,000
China (16 cities) Anti-hyperlipidaemia Market
(Projection Through 2014)
$500
2006 2007 2008 2009 2010 2011 2012 2013 2014
Year
Figure 2-6: China 16 cities Anti-hyperlipidaemia Market Projection
IMS Data: China Market
Competitive Landscape
The hyperlipidaemia market in China is crowded. All major anti-hyperlipidaemia brands have
been introduced in China including zocor@, lescol®, pravachol®, mevalotin®, and most
recently lipitor®. For each of these brands, the average retail daily dose (averaged across
different available dosage) is priced below $1, Table 2-3. Cholesterol drug regulators are often
categorized based on their mechanism of actions. In China, these categories include statins,
fibrates, and others (nicotinic acid, probucol, and pantosin). Cholestagel belongs to a class called
Bile Acid Sequestrants (BAS).
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zocor (merck)
lipitor (pfizer)
lescol(Novartis)
pravachol (Squibb)
mevalotin (sankyo)
$ 0.88
$ 0.89
$ 0.54
$ 0.91
$ 0.60
50,571
45,766
36,877
16,021
14,966
23
19
10
8
5
5,UUU
9,200
700
2,800
1,800
Table 2-3: Market Information on major anti-hyperlipidaemia brands in China (14, 15)
Current Treatments
o Statins:Well established and is the first line of treatment for hyperlipidaemia
o Bile Acid Sequestrant: Is quickly being phased out from treatment and invokes many
negative comments (old drug, GI side effect, limited effect of lowering LDL).
o Traditional Chinese Medicine (TCM): 19% of patients with liver disorders are treated
with TCM. TCMs are very inexpensive (<15 cents/daily dose).
New Entrants
* Zetia@: Schering Plough's Zetia® completed phase III clinical trials at the end of 2005
and is expected to launch in China in mid-2006. Schering Plough has undertaken large
marketing efforts to differentiate itself as an alternative to statins because it acts in the
intestines rather than the liver. Though Cholestagel® operates under a different
mechanism, because it too acts within the intestines, it will be inevitably compared to
Zetia® who gains a competitive advantage from being first-to-market and its small tablet
size of 10mg.
Government Policies
China entered the World Trade Organization (WTO) in 2001 and agreed to government policy
changes which would improve market access and allow for a more competitive environment.
Below is a look at some of the pharmaceutical-related regulation changes:
o Strengthened Patent Protection:
China will conform to a patent protection structure similar to the U.S. Patent legislation,
granting 20 year protection. The protection extends to substances, applications, and
manufacturing.
o Tariff Relaxation
Import duties were reduced 60% in 3 years starting in 2001, from 9.6% to 4.2%, to be
more in-line with developed countries. This applies to bulk pharmaceutical substances
and finished products.
o Distribution
Foreign manufacturers will be allowed to sell directly to wholesalers and retailers. They
will also allow for more foreign ownership of the wholesaling and retailing business.
Weaknesses in the System
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China's economy and government policies can best be described as in flux. The market
environment has seen much improvement but implementation of WTO policies has been slow
and requires monitoring by the industry. Some of the issues that exist include:
o Lengthy approval process: Registration (16)
The Registration process from filing to government market sale approval will take 2-2.5
years in China compared to 1-1.5 years in the U.S., Europe, and Japan. The delay in
processing comes in part because local clinical trials are mandatory for all drugs new to
the Chinese Market, even for drugs which have already gone through clinical trials in
other geographic regions.
o Protection of Intellectual Property:
The concept of patent protection and intellectual property rights is fairly new to China.
As a result, there is a lack of enforcement of patent legislation, and penalties are often
very low.
o Discrimination against foreign makers
Many domestically produced pharmaceuticals do not comply with good manufacturing
practices (GMP) standards observed in developed countries. Drug reimbursement
policies are also complex, where negotiation is required on a province by province basis.
Imported drugs are also often excluded unless the manufacturer agrees to large price cuts.
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40% ot the physicians interviewed were most interested in
combination therapy and over 30% believed that its non-s
action was a key advantage. Physicians felt that the big tab.
tolerable to older patients and therefore affect compliance. 1
Cholestagel was not as effective as existing drugs as a mono
In China, the hyperlipidaemia market in 2005 was $92 mil
rates of 28% for the past two years. Many of the major anti
brands have already been introduced at an average retail dail
Cholestagel will likely be compared to Zetia, which Sche
introduce into the China market in mid-2006.
Government policies are changing slowly to conform
However, the three year drug approval process is long by
intellectual property protection is still lax, and drug reim
favor domestic drugs.
MIT Thesis - Hong T. Hong Page 21 of 45
"
3 Supply Chain Evaluation
Market assessment alone is not enough to determine if it is financially sound to bring a
pharmaceutical product to a market. The second important step in the analysis focuses on the
supply chain. Supply chain evaluation takes into account four main factors: strategic factors,
market factors, company resource factors, and economic factors (Figure 3-1) (17). In this
chapter we will discuss these factors generally, and then consider them in detail for Genzyme's
product in China.
Step 3) Financial Modeling
Yes or No
Figure 3-1: Four key factors to supply chain evaluation
3.1 Strategic
Evaluating supply chain options often starts with weighing alternatives against the firm's
overarching strategy, overall objective. In some cases, an alternative may be more costly, but is
worth fully examining because it is a strategic fit. Another important part of the strategy is
determining what type of supply chain will be needed to support the business. An efficient
supply chain is more suitable to support stable products whereas a responsive supply chain better
supports innovative/rapidly changing business (18). In the case of biopharmaceutical products,
an efficient supply chain will often be more appropriate. Though the market demand may be
uncertain before market entry, after market entry these products usually have predictable product
life cycles. Some of the questions that should arise include:
o What is the firm's overarching strategy and what level of risk is the company willing to
accept inherent in emerging markets.
o Evaluate the strategic needs of the supply chain.
o Will the option facilitate market entry, time-to-market, or market access?
o Can future products benefit from this option?
o Will this bring intangible benefits like experience and brand recognition?
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Step 2) Supply Chain Evaluation
* Strategic Factors
* Market Factors
* Company Resource
Factors
* Economic Factors
:~:: i:- ii ---- i iii:i-:~ii-i iiii_ :-iii-:- :-iii~i- iiiiii~~i ii-:~i-ii i i~il~--- liii  ii-:ii
Step 1) Market Assessment L+
Page 22 of 45
3.2 Market
Market factors take into account industry and country dynamic as assessed in Chapter 2. A
company will often leverage external resources (suppliers, distributors, and local partners) within
the target market in an effort to lower costs and also mitigate risks. The company may benefit
from the external resource's unique expertise and knowledge of the target market. However
emerging markets often lack regulatory systems or contract-enforcing mechanisms which affect
accountability and reliability of the source. In addition, the local infrastructure including road
systems, railroads, airports, may not be able to support the firm's distribution of the product.
This may be especially critical for biopharmaceutical products which are temperature-sensitive.
Finally, it is helpful to understand the skill and expertise of the local partner as this will affect the
firm's level of future involvement. For example, firms in western markets have a lot of
experience in strategic marketing of branded products using direct-to-consumer advertising and
conducting doctor/hospital visits. This same level of marketing experience is not commonplace
in emerging markets where a majority of the sales products are generic or copy-cat drugs and do
not require a high level of marketing sophistication. These questions may be summarized as
follows:
o Are there external sources available in the market of interest?
o Can we be assured that the alternative meets quality, supply, and regulatory
requirements?
o Do local partners have the skill and expertise to fully support the brand?
3.3 Company Resources
A firm will need to choose its level of direct involvement based on assessing its internal
resources and in-house capabilities. These company resources include financial, technological,
production and marketing capabilities. Capital investments differ depending on the company's
level of involvement, i.e. exporting vs. in country manufacturing. As a result, the company must
make a reasonable decision about the amount of capital investment it can and is willing to make
in the emerging market. Information systems and information technology resources are also
critical to managing different components of the supply chain. Indeed, researchers have
identified information sharing as a critical aspect to operating extended supply chains (19). In
some cases firms can leverage existing production capacity to meet the demand needs of the new
market environment. Additional questions that may arise include:
o Are resources sufficient to meet short term and long term supply needs.
o Do we have existing contracts with external sources?
o How will the different links within the supply chain work together?
3.4 Economic
The economic factor is another key component in evaluating supply chain alternatives. How a
product is produced, who produces the product (internal vs. external sources), and where it is
produced will affect its costs of goods. Coordination costs associated with running remote
operations can be substantial and should be accounted for in any economic model. In emerging
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markets, the purchasing power of patients, governments, and healthcare organizations is often
low, which may hinder a company's ability to set a high sales price. As a result, the cost of
goods relative to market price is usually much higher than in traditional markets and this will in
turn affect company profits. However, as mentioned earlier, a firm may still decide that the
strategic factors outweigh the economic factors. Additional questions that may arise include:
o How long does it take to ramp up to production?
o Are there tax benefits with any of the alternatives?
o Can costs be mitigated by existing sales or future sales?
o Will the economics change if product volumes change?
3.5 Cholestagel Supply Chain Evaluation
Cost of Goods Relative to Market Wholesale Price
In Figure 3-2, we plot the cost of goods (raw material through tabletting) for WelChol against the
U.S. and (estimated) Chinese wholesale price. Considering the current cost structure, it is
doubtful that sales in China can be profitable. Therefore, it is important to look for alternative
supply chain structures that might lower the cost of goods for the China market.
Cost of Goods(US) Relative to Wholesale Price
China
COGS: Manufacturing Costs (Raw Material - Finished Product)
US: Profits (Genzyme & Partner) + (Marketing, Distribution, Rebates)
China: Profits (Genzyme & Partner) +(Marketing, Distribution, Rebates, VAT, import tax)
Figure 3-2: Cost of Goods for WelChol relative to US and (estimated) China Wholesale Price
Figure 3-3 details the WelChol supply chain from Raw Material production to Marketing &
Sales for the U.S. market. It includes a material flow diagram and material ownership
information. The supply chain involves four contract manufacturers located in four different
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countries. Genzyme does not make any portion of the product in-house and adds minimal
overhead cost to the final product. The company has 3 notable contracts:
* Genzyme & Contractor 1 (Cambrex)
Cambrex supplies raw material for both Genzyme's Renagel and WelChol products.
Genzyme directly purchases the raw material for the manufacturing of Renagel. DSM
(Contractor 2) purchases the raw material for WelChol on behalf of Genzyme, at rates
negotiated in the contract between DSM and Genzyme.
* Genzyme & Contractor 2 (DSM)
DSM purchases raw material from Cambrex as specified by the contract described above and
turns this material into a bulk polymer also known as active pharmaceutical ingredient, API.
DSM sends the bulk polymer to Contractor 3 (Powder Size) to mill/grind down to finer
particles. Genzyme purchases the milled API (ready for tabletting) from DSM at a set
contract price, and only interacts with Powder Size to control inventory levels.
* Genzyme & Sankyo U.S.
Sankyo purchases the milled API from Genzyme for a set contract price, not necessarily for
the same price Genzyme buys milled API from DSM. Sankyo takes the milled API through
tabletting, distribution, and finally marketing & sales.
Below we take a closer look at the main components of the supply chain and evaluate a number
of options considered for the China Market.
Material
Fl owx*
Ownership
Raw
lateria
I Contractor 1 j
API
Contractor 2
Mill
IGenzymel Sankyo US
Figure 3-3: WelChol Supply Chain
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Supplier -Cambrex -DSM -Powder Size -Patheon -Sankyo
Location -iowa & Sweden *Linz, Austria -Quakerstown, -Toronto, Canada -Parsippany,
Pennsylvania New Jersey
Contract -2006 -2014 -Warehouse -No Relationship ,2014
length with contract
Genzyme
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Raw Material: The bulk polymer Poly(allylamine hydrochloride) is the main ingredient in
Cholestagel.
Current
Cambrex is contracted to supply raw material for both Genzyme's Renagel and WelChol
products. WelChol utilizes approximately 5% and Renagel accounts for 95% of the total raw
material ordered. In the case of WelChol, contractor 2 (DSM) purchases the raw material
directly from Cambrex at the rates negotiated in the Genzyme contract. Poly(allylamine
hydrochloride), PAA, production requires low technology and all patents for this process have
expired.
Discussion
The contract with Cambrex expires in 2006. As a result, Genzyme's Operations team is
investigating whether to purchase the raw material from another source or to manufacture it in-
house. Renagel is Genzyme's second highest revenue generator, and uses a majority of the PAA.
The lowering of PAA costs will directly impact Renagel's cost of goods. For WelChol,
Genzyme does not have a direct contract with Cambrex, only a contract for the purchase of
milled API with DSM. Lowering of PAA costs will only impact WelChol's cost of goods if
Genzyme renegotiates with DSM to take over purchasing PAA. Genzyme has taken proposals
from a variety of sources including a number of Chinese suppliers. As of November, proposals
from a number of European sources have been significantly cheaper than both in-house
manufacturing options and proposals from Chinese manufacturers.
Recommendation
The Chinese government is interested in courting foreign direct investments that may bring in a
high level of technology into the country (20). Because PAA production is a low technology
process there may be low strategic benefits in setting up this type of manufacturing production in
the country. In addition, based on current proposals, such a move would likely increase raw
material costs for Genzyme's second highest product revenue generator, Renagel.
Active Pharmaceutical Ingredient (API) Production: API is the chemical entity that causes the
therapeutic response. In Cholestagel production, poly(allylamine) hydrochloride (PAA)
undergoes a cross-linking procedure with another chemical entity in a 12-step process to form
the active ingredient colesevelam hydrochloride. (Also known as bulk polymer)
Current
API production contributes 65% to the COGS of Cholestagel, and is the most complicated of
this drug production process. Genzyme negotiated a new contract with DSM in late 2004 giving
DSM API production rights until 2014, the year in which the patent of the product ends. With
this new contract Genzyme will receive a significant discount on API as order volumes increase.
Genzyme owns capacity at DSM that is significantly underutilized. The U.S. market demand has
not lived up to the forecast due to increased market competition and as a result, the facility is
only operating at 25% of its capacity. If it can increase utilization of that equipment, it will be
able to allocate the fixed costs over higher volume, thus reducing per unit costs.
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Discussion
There are a number of major hurdles that prevent Genzyme from moving API production to
China. Because intellectual property (IP) protection in China is still in the early stages of
development, there is much reluctance on the part of Genzyme's executives to hand over key
process information. Any unexpected delays or complications during transition to a Chinese
manufacturer could also affect Genzyme's relationship with its U.S. partner Sankyo. Finally,
estimated product sales in China do not warrant buying out the DSM contract or affecting
relationships with Sankyo.
Recommendation
Genzyme's management team wants minimal investment and minimum risk while entering
China with Cholestagel. Therefore, Genzyme should maintain its current relationship with its
API suppliers. At this time, Genzyme would not be able price Cholestagel at a competitive price
unless it applies the API volume discounts entirely to the China market. However, Genzyme
should be aware that Sankyo may also want to share in the increased profits as volume increases.
Milling: The bulk polymer of API, colesevelam 10 mesh, is pulverized into fine particles,
colesevelam 80 mesh. The particles undergo a sieve analysis in order to measure the particle
size property.
Current
Genzyme has no existing contract with the milling company, Powder Size. The API
manufacturer, DSM, owns a contract with the milling company. Estimates place milling costs at
about 2% of fully loaded cost of goods.
Discussion
There appears to be no large value or immediate reason to find an alternative milling source if
Genzyme chooses to buy out its contract with DSM. The milling process is not a high
technology process and would be unlikely to aid market entry because it is not viewed by the
Chinese government as a value-adding technology. In addition, the milling cost represents a
small portion of the entire costs. Therefore, efforts to reduce overall cost of goods should be
focused on higher value pieces of the supply chain.
Recommendation
Maintain current relationship
Current
Sankyo owns the milled WelChol product once it arrives at the Sankyo contract tabletting
facility, Patheon. Genzyme does not know the exact tabletting costs associated with making
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Tabletting: The milled API is processed with a number of excipients in a series of steps before it
is compressed and film-coated into a tablet. Each tablet contains 625mg of API. Excipients are
inert substances that act as fillers and aide in the delivery of a drug. Finished tablets are then
packaged in high density polyethylene bottles. Every lot of Cholestagel tablets then undergoes a
number of quality and stability tests.
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WelChol. However, they can estimate these costs based on tabletting experience with Renagel.
Initial estimates place tabletting at 20-25% of the entire cost of goods (assuming no API
discounts).
Discussion
A number of alternatives were considered for the tabletting of Cholestagel for the China market,
Figure 3-4. We evaluate each scenario below
(I)
Contractor Contractor Contractor TahIat
1 2 M lledRaw API ______ Package
Material3) Existing Facility
( 4) Build/Purchase
China plant
Figure 3-4: Tabletting production alternatives
1) Use Sankyo's tabletting source, Patheon.
Since Cholestagel tabletting should be no different from WelChol tabletting except for
the finished stamping of the drug name on each tablet, it would make sense to turn first to
Patheon as a viable tabletting source. Patheon has experience with the process and
therefore Genzyme would not need to go through the learning period required when
setting up a new process. Additionally, Genzyme would only need to purchase a
minimum amount of equipment, and therefore take a smaller financial risk. Sankyo
provided initial estimates that show tabletting costs will only be half the cost estimated
with tabletting at an existing Genzyme facility, Option 3. Tabletting costs may be much
lower than Genzyme facility because Cholestagel tabletting is only being charged
incremental costs and not overhead costs.
2) Contract tablet in China
Management was concerned about the lax IP protection in China and did not want to send
out process information for pricing purposes. However, a number of firms we visited in
China indicated they have modern tabletting capabilities and have invited Genzyme to
visit these facilities on future visits. Genzyme plans to investigate this option if the
company decides to take Cholestagel into the China market.
3) Use existing Genzyme tabletting capacity
Genzyme's tabletting site in Waterford, Ireland has enough capacity to take on
Cholestagel tabletting. However, the equipment is build for Renagel tabletting, slightly
MIT Thesis - Hong T. Hong Page 28 of45
different from Cholestagel tabletting. Genzyme would need to make a $1 million
investment in new quality control equipment and modification of existing equipment.
Finally, due to Genzyme's accounting treatment of overhead costs, Cholestagel would
have to bear some of the overhead costs that are largely due to Renagel tabletting, thus
reducing any cost benefits that might be achieved due to economies of scale. Of course,
this would help Renagel, as its overhead would go down.
4) Setting up tabletting facility in China
Investing in a new plant in China would only make economic sense if the facility could
also be used to tablet other products. The start-up costs for a new plant are far too high
for Cholestagel to bear alone. However, Genzyme's current product portfolio is highly
diverse and the only other product that could utilize such a facility is Renagel. Renagel
already has a Genzyme-own dedicated tabletting site in Waterford and moving tabletting
to China could be very costly considering the substantial fixed costs invested in this
existing plant.
Recommendation
The lowest investment and least risky option is Option 1: to use Sankyo's tabletting source.
Because many of the companies we spoke with have tabletting capabilities Option 2 also remains
an open possibility, but it would require executive level support.
Distribution: Sankyo U.S. is the sole distributor of WelChol and is responsible for providing the
product to hospital systems, physician's office, mail order facilities, and independent pharmacies
across the U.S.
Current
At this time, Genzyme does not have its own distribution channels within the country.
Discussion
The pharmaceutical distribution system in China is extremely competitive and highly complex.
It is a multi-level (tiered) system consisting of national suppliers, hundreds of provincial/regional
wholesalers, and thousands of local distributors (different from Hospital Tier I, II, III). Since
most distributors cover only a small area of the country, a company seeking broad geographic
coverage will need to utilize a large number of distributors (21). In an attempt to reform the drug
distribution system, the Chinese State Economic Trade Commission is starting to allow
multinationals to participate in establishing pharmacy chains and delivery centers. Since
Genzyme is so new to the Chinese market it seems most reasonable to rely on a company that
can navigate existing distribution networks rather than risk entanglement in this complex system.
Early discussions place distribution margins at around 5%-10% of retail price for each tier, and
there may be multiple tiers.
Cholestagel is a branded pharmaceutical product with cost of goods higher than the retail price of
most generic statins on the current Chinese market. Therefore, Cholestagel sales will most likely
be limited to the affluent. In addition, as we learned from market research (Chapter 2), patients
typically go to Tier III or Tier II hospitals for treatment and the purchase of pharmaceutical
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drugs. As a result, Genzyme will need to find a distributor with high penetration of Tier III and
Tier II hospitals in the 16 major cities.
During discussion with distributors in China, we learned that for highly competitive products,
distributors have to go through a bidding process in order to get their products into the hospital
pharmacy. In this bidding system wholesalers selling drugs in the same class enter into a bidding
war to gain 1-2 years exclusivity to supply to the hospital pharmacy. More hospitals are
participating in the bidding system to get distributors to provide deep discounts which are
leading to increased hospital margins on the sale of prescription drugs. The details of this
bidding system are not entirely clear to this author nor is it clear whether Cholestagel would have
to compete in such a process. However, more and more distributors are touting their ability to
enter successful bids. This topic warrants further investigation in the event Genzyme decides to
take Cholestagel to this market.
Recommendation
The pharmaceutical distribution system is far too complex and far too competitive for Genzyme
to go into alone. Since Genzyme is new to this market, the least risky option is to rely on a
company that can navigate the existing distribution networks. Early discussions place
distribution margins at around 5%-10% of retail price for each tier, and at least three tiers may be
involved (22). A distribution partner should have broad coverage of Tier III and Tier II hospitals
in the 16 major cities of China.
Marketing & Sales: Sankyo U.S. has a sizable group of sales representatives that call upon
physicians regularly providing information (pamphlets/brochures) and free drug samples.
Current
Genzyme has no marketing or sales force in China. The marketing sales force at Sankyo has
experienced a direct link between increased marketing efforts with increased WelChol sales.
Discussion
Based on market research, physicians are linking Cholestagel to an older version of bile-acid-
binder which has poor efficacy and tolerability. These preconceptions highlight the need to find
a strong marketing partner who can clarify the mechanism of Cholestagel to differentiate it from
the traditional bile acid binders and existing competition. This product will not sell if partners
distribute this product without a strong message. However, finding a strong marketing partner in
China may be difficult because Chinese companies often do not have this area of expertise (19).
As a result, Genzyme should expect to be more involved with promotion and marketing than
would normally be required in traditional markets.
The advertising of prescription drugs in the mass media has been banned; advertising is
permitted only in approved medical and trade journals. As a result marketing efforts focus
primary on physicians and not on the consumers (patients). Our market research shows that
physicians learn about new product information from medical journals (89%), medical
symposiums (85%), and visits from company representatives (63%). The ideal partner would
have access to all three information channels.
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Genzyme's ideal marketing partner for Cholestagel would have an established Cardiovascular
Disease Group, CVD, with a strong sales force and access to medical experts to attend
symposiums. This situation would be beneficial for both Genzyme and the partner. From
Genzyme's perspective, Cholestagel could more quickly reach peak sales because it would have
immediate access to a large network of doctors and hospitals. From the partner's perspective,
because it has existing sales representatives dedicated to this disease group, the company can
increase its product offering/sales without having to significantly increase costs. In fact, one
generic statin marketer expressed interest in Cholestagel as an add-on therapy to statin and did
not see Cholestagel as a direct competitor. This was an opportunity to meet the needs of
physicians interested in combination therapy treatment of hyperlipidaemia.
Marketing costs are likely to be high and market share is likely to be low for the first two years
that Cholestagel is on the market or at least up until Cholestagel is placed onto the drug
reimbursement list. It is still unclear what percentage of the retail price will go towards
marketing. Initial estimates range anywhere from 10% to 50% of retail price (11).
Recommendation
Genzyme needs a strong marketing partner who can help clarify the mechanism of Cholestagel
and differentiate it from the traditional bile-acid-binders. The ideal marketing partner would
have an established Cardiovascular Disease Group with resources to reach physicians in the
office, through medical journals, and at medical symposiums. Genzyme should expect marketing
costs to be significant while Cholestagel is not on the drug reimbursement list.
3.6 Recommended Supply Chain For Cholestagel China Market Entry
Table 3-1 below summarizes the supply chain recommendations discussed in this chapter. Aside
from API volume discounts being applied to Cholestagel for the China market, we were unable
to find additional cost savings through changes in the supply chain from Raw Material
production through Tabletting. The economics associated with the following recommendation
will be added into the financial evaluation model discussed at length in Chapter 4.
Table 3-1: Summary of Supply Chain Recommendation.
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Summary of Supply Chain Recommendation
Assume same supplier and cost structure (may change
depending on results from Renagel investigation)
API Maintain same supplier. All volume discount applied toChina market.
Milling No change (linked directly to API evaluation)
Tablefting Use Sankvo' s tabletting source
Distribution Form JV with distributor in China (focus on 16 major cities)
Mlarketing Find strong marketing partner with experience in CND
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4 Financial Evaluation Techniques
The third step in the framework (Figure 4-1) for analyzing pharmaceutical product introduction
in an emerging market involves financial modeling. The information from market assessment
(Chapter 2) and the cost component from our supply chain analysis (Chapter 3) are developed
into a financial model for final project evaluation. In this chapter we take a closer look at two
available financial analysis tools typically used in project evaluation: Net Present Value (NPV)
and Monte Carlo Simulation (23). However, the main focus will be on Monte Carlo Simulation,
a sophisticated technique that allows the user to explicitly account for uncertainty in the
information collected from market assessment and supply chain analysis.
Step 1) Market Assessment Step 2) Supply Chain Evaluation
Step 3) Financial Modeling
- NPV
* Monte Carlo Simulation
Yes: or No
Figure 4-1: A Focus on Financial Modeling
4.1 Net Present Value
Net Present Value (NPV) is a very popular method used across industries in project evaluation. It
is based on the principle that money today is worth more than an identical amount received in the
future. Therefore, financial evaluation of a project investment should reflect this time value of
money.
Figure 4-2 shows the formula for calculating NPV. The cost stream is subtracted from the cash
flow to obtain the net stream of revenues, which is then discounted to present value. A project
with a positive NPV indicates that future returns exceed investment expectations and, based on
financial reasons alone, the project should be accepted. The higher the NPV the more financially
valuable is the opportunity.
T C Co= Initial Investment
NPV = L- - C Ct= Cash Flow inyear t
t-1 (1 + r)t 1r= discount rate
T= time
Figure 4-2: Net Present Value Formula
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In order to calculate a project's NPV a company must forecast future cost and revenue streams
and identify an appropriate discount rate. The revenue likely to be generated by the project will
largely be dependent on the size of commercialization efforts, competition, and structure of the
market. A company must also choose an appropriate discount rate. The discount rate usually
reflects the return a company expects to earn on an alternative investment with the same risk
profile. In this case, the rate of return would have been comparable to other high risk
investment.
Advantages & Disadvantages of NPV
The advantage to using an NPV model is that it is simple and consistent. It is reasonable to use
this model for project evaluations when there are reliable sources of information and substantial
returns. There are however, a number of key disadvantages to the NPV approach. NPV is
deterministic and only focuses on the most likely project outcome. It does not account for risks
and assumes all revenues and costs are known, assigning single point estimates to variables that
have inherent uncertainty.
4.2 Monte Carlo Simulation
Many projects involve elements of uncertainty that are difficult to solve analytically and difficult
to assess visually. For example, variables such as growth rate, market size, and market share,
which may be elements in calculating expected returns, may each have a range of values
associated with them. Usually there are too many combinations of variables to calculate all
possible results. Monte Carlo simulation is a sophisticated technique that allows the user to
visually capture the range of outcomes associated with the project (24).
How Does It Work?
Software packages that utilize Monte Carlo simulation will simply use the spreadsheet model.
Each uncertain cell in your spreadsheet can be described with a range of possible values or
assigned a specific probability distribution based on historical data. Monte Carlo simulation
then generates independent random numbers for each uncertain cell, adhering to each cell's
defined probability distribution, and calculates an outcome. It is an iterative process, Figure 4-3,
and the simulation continues to run though the model until it reaches a designated maximum trial
run. The model then displays all of the results in a continuous distribution of outcomes along
with its associated probability, Figure 4-4.
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Simulation repeats until i reaches
user assigned trial number
Figure 4-3: Monte Carlo Simulation sample run (22)
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The variability in the outcome cell is a function of the variability in the input cells. Users can
often conduct sensitivity analysis to determine the impact of each input variable on the
distribution of expected outcomes. The simulations also provide the expected means, medians,
and modes of project outcomes and details the likelihood a project will meet or exceed its
expected result. All this information together is one way to assess project risk.
Mode
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Source: Effective organization and decision-making for long term growth: Business Insights, Steven Seget
Figure 4-4: Monte Carlo Simulation Outre- Illustration (21)
Advantages & Disadvantages of Monte Carlo
The advantage to using Monte Carlo simulation is that it makes risk more explicit and allows the
decision maker to see the full range of expected returns of investment. Monte Carlo Simulation
also uses NPV principles but the outcome is variable rather than fixed. Because the simulation
can undertake thousands of trials, it is fast and useful in evaluating complex projects. Software
that utilizes Monte Carlo simulation, usually conducts sensitivity analysis which allows the user
to identify key sources of risk and their impact. This in turn means users can more efficiently
use their time by focusing on specific variables to reduce the variance in the probability
outcomes. The disadvantage to Monte Carlo simulation is that it relies on the probability
assumptions made by the user and is more complex to develop and implement than NPV models.
4.3 Financial Modeling of the Cholestagel Project
The value of the Cholestagel introduction can be calculated as a discounted Profit stream
(Equation 4-1) or discounted Revenue Stream (Equation 4-2) from 2009 to 2014 (patent expires).
These streams are subject to uncertainty in market growth and market share. Mathematically we
have:
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GP n=9 r,(1+ )' i a t fGPF dY 1i=4 + ca)' P (I+fa)' (Equation 4-1)
AR =n=9 ro (1 + X)'-Y c (Equation 4-2)
i=4 (1 + a)'
The symbols are explained in the table below; random variables are in capital letters.
Symbol Description Value
GP Gross Profit Model output - random variable
AR Accumulated Revenue Model output - random variable
X Growth Rate (estimated) Random Variable 30%-50%
Triangular distribution
Y Cholestagel Market Share Random Variable 1-5% Triangular
distribution
ro Hyperlipidaemia Market (16 cities) $54 million
p Wholesale Price (estimated) Proprietary ($)
a Discount Rate 10%
ci Reimbursement Status constant V2 for i=4, 5 and 1 for i > 5
ai Cost of Goods (Raw Material- Tabletting) Proprietary ($/MT)
t Import Tax 4%
d Daily Dose of Pharmaceutical Ingredient 3.75 g
f Fixed Costs Proprietary ($ million)
Assumptions:
Below we list the assumptions taken into consideration during the financial analysis.
* Gross Profit: Does not include costs associated with Marketing and Distribution. These
values will need to be decided during negotiation before market entry. The Gross Profit
numbers that are output by the model must be large enough to reasonably cover marketing
and distribution costs.
* Hyperlipidaemia Growth: The hyperlipidaemia market includes sales of generic, local, and
branded pharmaceutical products. The calculations do not distinguish amongst the different
forms of products and will assume that the growth rate is the same for the entire market.
* Reimbursement Policy: Since each province has its own reimbursement list, achieving
reimbursement status will vary from province to province. However, to simplify the
calculation, we assumed that it would only require 2 years to achieve reimbursement status
for all 16 cities in their respective provinces.
* Cholestagel Market Share: Market share will be 50% of estimated maximum market share
for the two years the drug is not added to the reimbursement list.
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* Revenue Projection: The model only runs until the patent life of the drug ends in 2014. In
the U.S, generics often enter the market at the end of a branded drug's patent life,
significantly affecting the branded drug's market share. However, the concept of patent
protection and intellectual property rights is fairly new to China, so it is unclear at this point
how much sales will be affected once patent life ends.
* Losses Due to Parallel Trade: It is unlikely that products produced in China will affect
WelChol sales in the US. This risk was not added into the financial model
* Fixed Costs: Yearly recurring costs: Administrative Expense at Tabletting Site and
Genzyme, Tablet and Printing Tooling, Stability Tests, Release Testing, Maintaining
Import License
Up-Front Investments:
Up Front Investment costs are likely to range from roughly $1 to $1.5 million. This can be
considered a semi-fixed cost, meaning it only has be paid if they decide to sell Cholestagel in the
China Market, but it they do enter this market then this cost is independent of actual volume
sold. The main costs include: Registration, Clinical Trials, in-country quality testing site.
Results:
The Gross Profit (GP) and Accumulated Revenue (AR) are functions of the input variables and
since these quantities are random, GP and AR can be considered to be random variables
themselves. They are difficult to characterize analytically, but can be described with the help of
Monte Carlo simulation. I used Crystal Ball add-on to Excel to run my model. For proprietary
reasons, only results for Accumulated Revenue is shown below, Fig 4-5.
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Figure 4-5: Monte Carlo Simulation: Projected Accumulated Revenue for Cholestagel Sales
2009-2014
According to output of the model, the expected accumulated revenue from the venture is $31.6
million. However, there is considerable uncertainty around that number. In fact, the standard
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deviation is $15.9 million. There is a 70% probability to have accumulated revenue be between
$15.7 million and $47.5 million. The accumulated revenue displays a factor three difference
within one standard deviation of the mean and is indicative of the risk and uncertainty associated
with this venture.
Figure 4-5 does not account for the costs to produce, market, or distribute Cholestagel. Genzyme
has a good estimate on production costs, but does not have great estimates for marketing and
distribution in China. From previous discussion in Section 3.5 Cholestagel Supply Chain
Evaluation we are reminded that drug pricing in China is much lower than in the U.S. As a
result production, marketing, and distribution costs will be a large percentage of drug sale price
and significantly affect what Genzyme will receive in profits. Based on our experience with
WelChol in the U.S., on average Genzyme receives approximately 8% of Gross Revenue. This
royalty is pure profit. If we assume the same royalty structure for the China market, we can get a
continuous distribution of possible accumulated royalty with its associated probability by
multiplying accumulated revenue by 8%. Figure 4-6, shows the output of the Monte-Carlo
Model and highlights the accumulated royalty of $1.5 million, the point where Genzyme breaks
even on its upfront $1.5 million investment. In Table 4-1, we list the probability to achieve
various accumulated royalty streams (column 2) and list the average value in column 3,
assuming six years of sales. The table shows a high probability for Genzyme to break-even, 78%
probability of reaching $1.5 million. However, there is only a 40% chance Genzyme will make
$2.6 million accumulated royalty or $1.1 million in total profits after taking out investment costs.
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Probability Accumulated Per Year
(%) Royalty Royalty
($ million) ($ million)
100 0.73 0.12
90 1.17 0.19
80 1.43 0.24
70 1.69 0.28
60 1.96 0.33
50 2.26 0.38
40 2.58 0.43
30 2.97 0.49
20 3.46 0.58
10 4.25 0.71
0 9.90 1.65
Table 4-1: Probability of achieving various Cholestagel royalty streams in China
4.4 Conclusion
In this thesis, I have developed a three-step framework that emphasizes a data-driven approach
for analyzing the potential for introducing a pharmaceutical product into a predetermined
emerging market. The first step is market assessment which relies on information gathered from
primary data (current and prospective customers) and secondary data (third party sources) to
better understand the competitive environment. The second step focuses on the supply chain.
Information from market research is used to propose and evaluate alternative operational
structures, to reduce costs, and to facilitate market entry.
The third-step involves financial modeling of the venture. Because entering an emerging market
is characterized by a great deal of uncertainty, I focused on probabilistic Monte Carlo models.
This enabled me to make explicit many of the risks and uncertainties inherent in the venture.
Rather than having very speculative discussions of possible project outcomes, discussions could
be narrowed down to a more structured and fact-based analysis of specific input variables.
Modern simulation tools enabled us to see how uncertainties in these assumptions translated into
a range of possible project outcomes. This probability distribution of outcomes could then be
compared with the company's overall strategic objectives and willingness to take risk, in order to
make a sensible final decision.
The framework was used to analyze Genzyme's possible introduction of the cholesterol lowering
drug, Cholestagel (WelChol as it is known in the U.S.), into the urban Chinese market. The case
study conclusions are outlined below:
The hyperlipidaemia market is China was valued at $92 million in 2005 with impressive growth
rates of nearly 30% in the past two years. However, the market is competitive and all of the
major anti-hyperlipidaemia brands have already been introduced. Physicians were most
interested in Cholestagel as a combination therapy and believed that its non-systemic mode of
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action was a key advantage. Even so, physicians were quick to compare Cholestagel to Zetia, a
Schering Plough product with similar attributes which is expected to appear on the China Market
in mid-2006. Without a strong key differentiator, Cholestagel might be forced to compete on
price.
On the cost side, aside from API volume discounts being applied to Cholestagel for the China
market, we were unable to find additional cost savings through changes in the supply chain from
Raw Material production through Tabletting. Production, marketing, and distribution costs will
be a large percentage of drug sale price and significantly affect what Genzyme will receive in
profits.
Genzyme collects approximate $10 million per year in royalties from the sale of WelChol in the
U.S. Assuming this royalty remains constant until the patent expires in 2014, the net present
value of the accumulated WelChol royalty is $63 million, discounted at 10%. The financial
Monte Carlo model suggests that the Cholestagel venture in China has a high 78% probability of
breaking even, reaching $1.5 million. However, there is only a 40% probability of making an
additional $2.6 million in accumulated royalty or $1.1 in total profits by the end of 2014.
Cholestagel sales in China would represent 1.7% increase in profits from what Genzyme
achieves with WelChol. The expected financial returns do not justify deploying Genzyme
resources to manage Cholestagel in this new market environment. Finally, we mention that
Genzyme is nevertheless considering taking Cholestagel into the Chinese market for non-
economic strategic reasons such as gaining market experience and creating brand awareness.
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5 Appendix A
Sources of International Marketing Data
Market research is critical piece to evaluating whether introducing a product into a new market is
advisable. Arguably, the most challenging aspect of evaluating an international market,
especially one in a developing country, is obtaining reliable data.
Obtaining reliable information requires persistence, a little creativity, and use of good judgment.
Below is a look at the challenges in collecting primary and secondary international marketing
data, and ways in which to obtain free or low-cost information (25).
Primary vs. Secondary Research
Ideally, business plans should be evaluated based on primary data, data collected specifically for
the project plan in question. In comparison to secondary data, which comes from existing third
party sources, primary data is more accurate, relevant, and timely. Companies will typically
start with secondary sources before turning to costly primary data. For developing markets,
collecting primary or secondary data can be extremely challenging.
Obstacles to Collecting Secondary Data in Emerging markets
° Lack of Current Data
In the U.S., we are accustomed to having access to up-to-date data. For example, in the
U.S., a Red Book is published each year listing wholesale prices for drugs. Similar books
for drugs on the major European markets can easily be found online or with a little
searching in libraries. However, in developing countries, similar data is more likely to be
collected every 5 to 10 years or not collected at all.
• Costs of Obtaining Secondary Data
When government spending on statistical reporting is low, companies must rely on
specialized agency data collection. Because of the challenges in collecting accurate and
timely data, these agencies can charge a premium price for the information.
o Comparability
Data collection methods can differ between sources and can lead to conflicting data. Be
careful to understand how the numbers are defined.
Obstacles to Collecting International Primary Data
Colleting primary data can have its own difficulties. Below is a list of some of these challenges.
° Language
Communicating with people in a foreign market is more challenging because of the
language barrier. Surveys have to be translated, and reverse translated in order to assess
if the data collected is consistent with research goals. Even then, there are always
moments of miscommunication leading to increased delays in completing the research.
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o Cultural
Cultural attitudes can affect how subjects respond towards research surveys. Some
societies are uncomfortable with sharing personal information or opinions. Out of
politeness, some respondents may choose to agree with opinions in a group setting (focus
groups), and are more apt to provide true opinions on a one-to-one interview.
o Infrastructure
Local infrastructure may affect data collection techniques applied for the market research.
In the U.S., there are sophisticated telephone software and internet survey methods,
which can provide affordable and accurate surveys. In foreign markets, where there are
infrastructure constraints, primary data rely on face-to-face interviews, which are more
prone to error. In addition, this survey method limits the size of the interview pool due to
time constraints.
Recommendations for Resolving International Data Challenges
There are a number of resources, free or low-cost, which can help mitigate some of the data
challenges faced during market research.
Public Resources
*. Scientific Journals: This researcher found epidemiology reports to be an excellent source
of statistical information. The studies are specific to a disease group and can provide
prevalence information which can be used in market sizing.
+*° Industry Press: Newspapers and industry magazines like The Wall Street Journal, New
York Times, and the Harvard Business Review will often detail competing company
activities. Company literature and websites are also good sources of competitive
intelligence.
° Databases: There are government databases with statistical information such as
population, GDP, and per capita income. These websites include STAT-USA (www.stat-
usa.gov), CIA World Factbook (www.cia.gov/cia/publications/factbook), and National
Bureau of Statistics of China www.stats.gov.cn/enGliSH/)
** Specialized Research Reports: Most detailed research reports must be purchased from
specialized companies but occasionally detailed reports can be found through the
university library resources, or outdated/stripped down versions might be posted on-line.
Networking
+ Personal Resource: This researcher was able to speak to someone who had worked in the
Chinese healthcare industry, and to a regular purchaser of cholesterol lowering drugs in
China.
- Company Resource: It may be fruitful to speak with employees within other business
units, who may have experience in either entering new markets or in entering the market
of interest. These individuals may already have the information you are seeking or have
access to relevant resources.
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6 Appendix B
Market Research Study
Genzyme hired a marketing firm to conduct primary research to better understand the anti-
hyperlipidaemia market in China. The research included focus groups and face-to-face
interviews with physicians at top tier hospitals in 6 major urban cities. The study was started in
October 2005 and was completed at the end of December 2005. The information gathered
focused on the following key deliverables:
* To explore the potential of Cholestagel in the anti-hyperlipidaemia market in China
o An analysis of the market with regard to geography (city tiers) and IMS
data analysis
o Reimbursed sales vs. out-of-pocket purchasers
o Points of distribution (hospital or retail pharmacy channels)
o Age analysis of patients
o Pipeline products scheduled to enter the market
o Pricing structure of all existing therapies
* To identify potential market positions for Cholestagel, both currently and in the
future.
Focus Group Interviews
o Chief Doctor (CD) or Vice-Chief Doctor (VCD) level physicians were recruited from
Tier III hospitals (highest level)
o Two focus groups were conducted, each lasting 90-120 minutes, one in Shanghai and
one in Beijing.
Beijing Hospitals: 7 physicians Department & Seniority
Tongren Hospital Cardiology (VCD)
Ji shui tan Hospital Cardiology (CD)
Ren ming Hospital Cardiology (VCD)
Beijing Hospital Cardiology (CD)
Chao yang Hospital Geriatrics (VCD)
Zhong ri Hospital Geriatrics (VCD)
You yi Hospital Cardiology (VCD)
Shanghai Hospitals: 6 physicians
Huashan Hospital Geriatrics (CD)
Shanghai NO.1 Hospital Geriatrics (VCD)
Rui jin Hospital Cardiology (VCD)
Shanghai NO.9 Hospital Cardiology (VCD)
Shuguang Hospital Cardiology (CD)
Navy NO. 411 Hospital Cardiology (CD)
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Face-to-Face Interviews
o Interviews lasted around 30 minutes each. The questionnaire followed a semi-structured
format, including both open and closed questions.
o A total of 160 doctors were interviewed.
o At the end of the interview the doctors were asked to fill in at least 10 hyperlipidaemia
patient diary forms. Each form covered the demographics, diagnosis and treatment of
patients receiving therapy for their hyperlipidaemia.
I Crnnt CnI 0/
China Visit
Top managers in the
Cholestagel, including
distribution partners.
Beijing and Shanghai.
pharmaceutical division at Genzyme, the
this researcher, visited China to meet with
The one week trip began November 27,
business unit that manages
five potential marketing and
2005 and included visits to
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